Mariann Churchwell, Pharm.D., BCPS, FCCP
PUBLICATIONS AND JOURNALS
Abstracts
1. Churchwell MD, Parker, D. Jr., Carhaupoma, JR, Kraus J, Coplin WM, Rhoney DH. Prospective Evaluation of Feeding Tolerance of Continuous Versus Bolus Early Enhanced Gastric Feeding in Brain-injured Patients. 2002 American Society of Health System Pharmacists Midyear Clinical Meeting, Atlanta, Georgia. December 2002.
2. Pasko DA, Churchwell MD, Mueller BA. Influence of Ultrafiltrate Production Rate on Sieving Coefficient (SC) in Continuous Venovenous Hemofiltration (CVVH). Blood Purif 2004;22:229-47.
3. Pasko DA, Churchwell MD, Mueller BA. Development of an In vitro Model of Continuous Renal Replacement Therapy (CRRT) Solute Removal. Blood Purif 2004;22:229-47.
4. Churchwell MD, Pasko DA, Mueller BA. Comparison of Diffusive and Convective Clearance with AN69 and Polysulfone Hemodiafilters in CVVH and CVVHD. Blood Purif 2004;22:229-47.
5. Pasko DA, Churchwell MD, Mueller BA. Duration of Continuous Hemofiltration and Ultrafiltration Rate Influence on Sieving Coefficients. 2004 European Society of Clinical Pharmacy Conference, Paris, France. April 2004.
6. Pasko DA, Churchwell MD, Mueller BA. Duration of Continuous Venovenous Hemodialysis and Dialysate Flow Rate on Solute Saturation Coefficient. 2004 European Society of Clinical Pharmacy Conference, Paris, France. April 2004.
7. Sirithanakul K, Mohammed AS, Churchwell MD, Somerville A, Kurtz J, Mubarak KK. Amelioration of Subcutaneous Treprostinil Pain with a Lidocaine Patch. 2004 American Thoracic Society Orlando FL. May 2004.
8. Churchwell MD, Pasko DA, Mueller BA. CVVH Transmembrane Clearance of Daptomycin with Two Different Hemodiafilters. Pharmacother 2004;24:1447.
9. Churchwell MD, Pasko DA, Mueller BA. CVVHD Transmembrane Clearance of Daptomycin with Two Different Hemodiafilters. 2004 Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C. October 2004.
10. Mueller BA, Churchwell MD, Pasko DA, Smoyer WE. Enhanced Valproic Acid Dialytic Clearance with an Albumin-based Dialysate in Continuous Venovenous Hemodialysis. Blood Purif 2005;23:149-74.
11. Grio M, Churchwell MD. Pasko DA, Smoyer WE, Mueller BA. Albumin-Supplemented Dialysate Does Not Enhance Clearance of Phenytoin (PHT) during In vitro Continuous Venovenous Hemodialysis (CVVHD) American Society of Nephrology 2005 Renal Week. November 2005 Philadelphia, PA.
12. Churchwell MD. Pasko DA, Smoyer WE, Mueller BA. Albumin-Supplemented Dialysate Enhances Clearance of Carbamazepine (CBZ) during In vitro Continuous Venovenous Hemodialysis (CVVHD) American Society of Nephrology 2005 Renal Week. November 2005 Philadelphia, PA.
13. Churchwell MD. Pasko DA, Smoyer WE, Mueller BA. Albumin-Supplemented Dialysate Enhances Clearance of Valproic Acid (VPA) during In vitro Continuous Venovenous Hemodialysis (CVVHD). American Society of Nephrology 2005 Renal Week. November 2005 Philadelphia, PA.
14. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. Hydroxypropyl Beta Cyclodextrin Transmembrane Clearance during In vitro Continuous Venovenous Hemofiltration (CVVH). Blood Purif 2006;24:267 (Abstract #46).
15. Pasko DA, Churchwell MD, Btaiche IF, Jain JC, Mueller BA. Trace Element Clearance in Pediatric Patients Supported by Continuous Venovenous Hemodiafiltration (CVVHDF) Blood Purif 2006;24:269 (Abstract #49).
16. Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA. Trace Element Clearance in Critically Ill Patients Treated with Continuous Venovenous Hemodiafiltration (CVVHDF) Blood Purif 2006;24:268 (Abstract #47).
17. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. Telavancin transmembrane clearance during in vitro continuous venovenous hemofiltration. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 2006 Nice, France.
18. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. Telavancin pharmacokinetics during in vitro continuous venovenous haemodialysis. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 2006 Nice, France.
19. Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA. Trace Element Clearance in Critically Ill Patients Treated with Continuous Venovenous Hemodiafiltration (CVVHDF) 2006 American College of Clinical Pharmacy (ACCP) Annual Meeting October 2006 St. Louis, MO Pharmacotherapy 2006;26:e76 (Abstract #164E).
20. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. 2-Hydroxypropyl Beta Cyclodextrin Transmembrane Clearance During in Vitro Continuous Venovenous Hemodialysis. 2007 American College of Clinical Pharmacy (ACCP) Spring Meeting April 2007 Memphis, TN Pharmacotherapy 2007;27:e17-18 (Abstract #51) Finalist Best Poster Award.
21. Dotson B, Churchwell M, Pharm.D. Retrospective Evaluation of Circuit Survival Time for Continuous Renal Replacement Therapy at the University of Toledo Medical Center. American Society of Health-System Pharmacy 2007 Mid-Year Meeting Las Vegas, NV.
22. Stevenson JM, Churchwell MD, Patel JH, DePestel DD, Sörgel F, Vilay AM, Mueller BA. Ertapenem Transmembrane Clearance During Modeled Continuous Hemodialysis. Blood Purif 2008;26:173 (Abstract #21).
23. Stevenson JM, Churchwell MD, Patel JH, DePestel DD, Sörgel F, Vilay AM, Mueller BA. Ertapenem Transmembrane Clearance During Modeled Continuous Hemofiltration. Blood Purif 2008;26:172 (Abstract #20).
24. Churchwell MD, Tam VH Hou JG. Colistin Clearance during Continuous Dialysis. Blood Purif 2008;26:171 (Abstract #17).
25. Peeters MJ, Churchwell MD, Mauro LS, Cappelletty DM, Stone GE. A Rasch-based Pharmacotherapeutics Textbook Selection Methodology. American Associations of Colleges of Pharmacy July 2008 Chicago, IL.
26. Salama NN, Segal J, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. Intradialytic Administration of Daptomycin in End Stage Renal Disease and Patients on Hemodialysis. J Am Soc Nephrol 2008;19:737A (Abstract #SA-PO2772).
27. Salama NN, Segal J, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. Daptomycin Serum Concentrations are Maintained in a 2- and 3-Day Interdialytic Period. J Am Soc Nephrol 2008;19:738A (Abstract #SA-PO2773).
28. Churchwell MD. Vancomycin Clearance during Slow Low Efficiency Dialysis. Pharmacother 2009;29(10):220-221e (Abstract #135).
29. Zukkoor S, Mauro V, Churchwell M. Atorvastatin 80 mg Daily Therapy for Acute Coronary Syndrome: An Assessment of Short and Long Term Tolerability. Ohio College of Clinical Pharmacy October 2009 Cleveland, OH (Abstract #30).
30. Zukkoor S, Mauro V, Churchwell M. Atorvastatin 80 mg Daily Therapy for Acute Coronary Syndrome: An Assessment of Short and Long Term Tolerability. 44th American Society of Health-System Pharmacy 2009 Mid-Year Meeting Las Vegas, NV.
31. Murray TD, Churchwell MD, Vilay AM, Mueller BA. Anticonvulsant drug clearance by in vitro models of slow low efficiency dialysis, continuous veno-venous hemofiltration, and continuous dialysis with albumin-supplemented dialysate. 45th American Society of Health-System Pharmacy 2010 Mid-Year Meeting Anaheim, CA.
32. Churchwell MD, Jung R, Ratnam S. Early versus late conversion to sirolimus from calcineurin inhibitor based immunosuppression in adult kidney transplant recipients: a single center retrospective study. American Society of Nephrology Renal Week 2011 Philadelphia, PA.
33. Hoover MJ, Mauro VF, Gundrum TE, Churchwell MD. Evaluating the role of statins in the prevention of contrast-induced nephropathy. 46th American Society of Health-System Pharmacy 2011 Mid-Year Meeting New Orleans, LA.
34. Khan A, Churchwell M, Gundrum T, Malhotra D. Predictors of resistance to erythropoietin therapy in chronic kidney disease. 47th American Society of Health-System Pharmacy 2012 Mid-Year Meeting Las Vegas, NV.
35. Thompson, E, Churchwell M, Jung R. Bleeding Risk Associated with Antiplatelet Therapy in Chronic Kidney Disease Patients Following Acute Coronary Syndrome. 47th American Society of Health-System Pharmacy 2012 Mid-Year Meeting Las Vegas, NV.
36. Verlinden N, Thompson E, Churchwell M, Jung R. Bleeding Risk Associated with Antiplatelet Therapy in Chronic Kidney Disease Patients Following Acute Coronary Syndrome. 48th American Society of Health-System Pharmacy 2013 Mid-Year Meeting Orlando, FL.
37. Sejnowski C, Johnson K, Churchwell M, Vetteth S, Shafique I and Prashar R. Prospective Comparison of Loop diuretic and albumin infusion regimens in Patients with Acute Kidney Injury. 48th American Society of Health-System Pharmacy 2013 Mid-Year Meeting Orlando, FL.
38. Wei Y, Yang W, Boddu S.H.S, Jung R, Churchwell MD. Compatibility, stability, and efficacy of vancomycin combined with gentamicin or ethanol in sodium citrate as a catheter lock solution. Student College of Clinical Pharmacy 1st annual research symposium 2014. Toledo, OH.
39. Johnson K, Sejnowski CA, Vetteth S, Shafique I, Prashar R, Jung R, Churchwell M. Loop Diuretic Infusions With & Without Continuous Albumin Infusions in Acute Kidney Injury Patients, Society of Critical Care Medicine 2015 Phoenix, AZ.
40. Radan J, Eitniear LA; Churchwell M, Jung R, Ortiz J. The Association Between Tacrolimus Levels and Graft Loss in Renal Transplant Patients. 51st American Society of Health-System Pharmacy 2016 Mid-Year Meeting Las Vegas, NV.
41.Frank M, Boddu SH, Mauro VF, Churchwell MD. Compatibility of valproic acid injection with select cardiovascular medications. Student College of Clinical Pharmacy 4th annual research symposium 2017. Toledo, OH.
Peer-Reviewed Articles
1. Churchwell MD, Pasko DA, Mueller BA. Daptomycin Clearance during Modeled Continuous Renal Replacement Therapy. Blood Purif 2006;24:548-554.
2. Churchwell MD and Mueller BA. Selected Pharmacokinetic Issues in Patients with Chronic Kidney Disease. Blood Purif 2007;25(1):133-8.
3. Churchwell MD, Pasko DA, Btaiche IF, Jain J, Mueller BA. Trace Element Removal during In vitro and In vivo Continuous Hemodialysis. Nephrol Dial Transplant 2007;22(10):2970-2977.
4. Churchwell MD, Btaiche IF, Pasko DA, and Mueller BA. Reply: Nephrol Dial Transplant 2008;23:1462-63.
5. Churchwell MD, Pasko DA, Smoyer WE and Mueller BA. Enhanced Clearance of Highly Protein-bound Drugs by Albumin Dialysate during Modeled Continuous Hemodialysis. Nephrol Dial Transplant 2009;24(1):231-8.
6. Vilay AM, Churchwell MD, Mueller BA. Drug Metabolism and Clearance in Acute Kidney Injury. Crit Care 2008;12(6):235.
7. Stevenson JM, Patel JH, Churchwell MD, Vilay AM, Depestel DD, Sörgel F, Kinzig M, Jakob V, Mueller BA. Ertapenem Clearance during Modeled Continuous Renal Replacement Therapy. Int J Artif Organs 2008;31(12):1027-34.
8. Pasko DA, Churchwell MD, Btaiche IF, Jain J, Mueller BA. from the Renal Replacement Therapy Kinetics Study Group. Continuous Venovenous Hemodiafiltration Trace Element Clearance in Pediatric Patients: A Case Series. Pediatr Nephrol 2009;24(4):807-13.
9. Churchwell MD, Mueller BA. Drug Dosing during Continuous Renal Replacement Therapy. Semin Dial 2009 Mar-Apr;22(2):185-8.
10. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. Intradialytic Administration of Daptomycin in End Stage Renal Disease Patients on Hemodialysis. Clin J Am Soc Nephrol 2009;4(7):1190-4.
11. Patel JH, Churchwell MD, Seroogy JD, Barriere SL, Grio M, Mueller BA. Telavancin and Hydroxy propyl-beta-cyclodextrin Clearance during Continuous Renal Replacement Therapy: an In vitro Study. Int J Artif Organs. 2009 Oct;32(10):745-51.
12. Salama NN, Segal JH, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. Single-dose Daptomycin Pharmacokinetics in Chronic Haemodialysis Patients. Nephrol Dial Transplant. 2010 Apr;25(4):1279-84.
13. Peeters MJ, Churchwell MD, Mauro LS, Cappelletty DM, Stone GE. A Student-inclusive Pharmacotherapeutic Textbook Selection Process. Currents in Pharmacy Teaching & Learning 2010:2(1):31-38.
14. Vilay AM, Shah KH, Churchwell MD, Patel JH, DePestel DD, Mueller BA. Modeled Dalbavancin Transmembrane Clearance during Intermittent and Continuous Renal Replacement Therapies. Blood Purif. 2010 Jun 24;30(1):37-43.
15. Dotson B, Lynn S, Savakis K, Churchwell MD. Physical Compatibility of 4% Sodium Citrate with Selected Antimicrobial Agents. Am J Health Syst Pharm. 2010 Jul 15;67(14):1195-8.
16. Dotson B, Churchwell MD. Physical Compatibility of Catheter Lock Solutions with 4% Sodium Citrate and 18% Saline, Fluconazole, and Micafungin. Am J Health Syst Pharm2011 Mar 1;68(5):377-8.
17. Pasko DA, Churchwell MD, Salama NN, Mueller BA: Longitudinal Hemodiafilter Performance in Modeled Continuous Renal Replacement Therapy. Blood Purif 2011;32:82-88 (DOI: 10.1159/000324191)
18. Churchwell MD. Use of an in vitro model of renal replacement therapy systems to estimate extracorporeal drug removal. J Clin Pharmacol. 2012 Jan;52(1 Suppl):35S-44S.
19. Mueller BA, Jasiak KD, Thiel SR, Stevenson JM, Vilay AM, Scoville BA, Churchwell MD, Pasko DA, Perkins N. The Effects of Vibration on the Clearance of Various Molecular Weight Solutes during in vitro Dialysis. ASAIO J. 2013 Mar;59(2):140-144.
20. Churchwell MD, Parker, D. Jr., Carhaupoma, JR, Kraus J, Coplin WM, Rhoney DH. Prospective Evaluation of Feeding Tolerance of Continuous Versus Bolus Early Enhanced Gastric Feeding in Brain-injured Patients. 2002 American Society of Health System Pharmacists Midyear Clinical Meeting, Atlanta, Georgia. December 2002.
21. Pasko DA, Churchwell MD, Mueller BA. Influence of Ultrafiltrate Production Rate on Sieving Coefficient (SC) in Continuous Venovenous Hemofiltration (CVVH). Blood Purif 2004;22:229-47.
22. Pasko DA, Churchwell MD, Mueller BA. Development of an In vitro Model of Continuous Renal Replacement Therapy (CRRT) Solute Removal. Blood Purif 2004;22:229-47.
23. Churchwell MD, Pasko DA, Mueller BA. Comparison of Diffusive and Convective Clearance with AN69 and Polysulfone Hemodiafilters in CVVH and CVVHD. Blood Purif 2004;22:229-47.
24. Pasko DA, Churchwell MD, Mueller BA. Duration of Continuous Hemofiltration and Ultrafiltration Rate Influence on Sieving Coefficients. 2004 European Society of Clinical Pharmacy Conference, Paris, France. April 2004.
25. DA, Churchwell MD, Mueller BA. Duration of Continuous Venovenous Hemodialysis and Dialysate Flow Rate on Solute Saturation Coefficient. 2004 European Society of Clinical Pharmacy Conference, Paris, France. April 2004.
26. Sirithanakul K, Mohammed AS, Churchwell MD, Somerville A, Kurtz J, Mubarak KK. Amelioration of Subcutaneous Treprostinil Pain with a Lidocaine Patch. 2004 American Thoracic Society Orlando FL. May 2004.
27. Churchwell MD, Pasko DA, Mueller BA. CVVH Transmembrane Clearance of Daptomycin with Two Different Hemodiafilters. Pharmacother 2004;24:1447.
28. Churchwell MD, Pasko DA, Mueller BA. CVVHD Transmembrane Clearance of Daptomycin with Two Different Hemodiafilters. 2004 Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, D.C. October 2004.
29. Mueller BA, Churchwell MD, Pasko DA, Smoyer WE. Enhanced Valproic Acid Dialytic Clearance with an Albumin-based Dialysate in Continuous Venovenous Hemodialysis. Blood Purif 2005;23:149-74.
30. Grio M, Churchwell MD. Pasko DA, Smoyer WE, Mueller BA. Albumin-Supplemented Dialysate Does Not Enhance Clearance of Phenytoin (PHT) during In vitro Continuous Venovenous Hemodialysis (CVVHD) American Society of Nephrology 2005 Renal Week. November 2005 Philadelphia, PA.
31. Churchwell MD. Pasko DA, Smoyer WE, Mueller BA. Albumin-Supplemented Dialysate Enhances Clearance of Carbamazepine (CBZ) during In vitro Continuous Venovenous Hemodialysis (CVVHD) American Society of Nephrology 2005 Renal Week. November 2005 Philadelphia, PA.
32. Churchwell MD. Pasko DA, Smoyer WE, Mueller BA. Albumin-Supplemented Dialysate Enhances Clearance of Valproic Acid (VPA) during In vitro Continuous Venovenous Hemodialysis (CVVHD). American Society of Nephrology 2005 Renal Week. November 2005 Philadelphia, PA.
33. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. Hydroxypropyl Beta Cyclodextrin Transmembrane Clearance during In vitro Continuous Venovenous Hemofiltration (CVVH). Blood Purif 2006;24:267 (Abstract #46).
34. Pasko DA, Churchwell MD, Btaiche IF, Jain JC, Mueller BA. Trace Element Clearance in Pediatric Patients Supported by Continuous Venovenous Hemodiafiltration (CVVHDF) Blood Purif 2006;24:269 (Abstract #49).
35. Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA. Trace Element Clearance in Critically Ill Patients Treated with Continuous Venovenous Hemodiafiltration (CVVHDF) Blood Purif 2006;24:268 (Abstract #47).
36. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. Telavancin transmembrane clearance during in vitro continuous venovenous hemofiltration. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 2006 Nice, France.
37. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. Telavancin pharmacokinetics during in vitro continuous venovenous haemodialysis. 16th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) April 2006 Nice, France.
38. Churchwell MD, Pasko DA, Btaiche IF, Jain JC, Mueller BA. Trace Element Clearance in Critically Ill Patients Treated with Continuous Venovenous Hemodiafiltration (CVVHDF) 2006 American College of Clinical Pharmacy (ACCP) Annual Meeting October 2006 St. Louis, MO Pharmacotherapy 2006;26:e76 (Abstract #164E).
39. Patel JH, Grio MC, Churchwell MD, Seroogy J, Barriere S, Mueller BA. 2-Hydroxypropyl Beta Cyclodextrin Transmembrane Clearance During in Vitro Continuous Venovenous Hemodialysis. 2007 American College of Clinical Pharmacy (ACCP) Spring Meeting April 2007 Memphis, TN Pharmacotherapy 2007;27:e17-18 (Abstract #51) Finalist Best Poster Award.
40. Dotson B, Churchwell M, Pharm.D. Retrospective Evaluation of Circuit Survival Time for Continuous Renal Replacement Therapy at the University of Toledo Medical Center. American Society of Health-System Pharmacy 2007 Mid-Year Meeting Las Vegas, NV.
41. Stevenson JM, Churchwell MD, Patel JH, DePestel DD, Sörgel F, Vilay AM, Mueller BA. Ertapenem Transmembrane Clearance During Modeled Continuous Hemodialysis. Blood Purif 2008;26:173 (Abstract #21).
42. Stevenson JM, Churchwell MD, Patel JH, DePestel DD, Sörgel F, Vilay AM, Mueller BA. Ertapenem Transmembrane Clearance During Modeled Continuous Hemofiltration. Blood Purif 2008;26:172 (Abstract #20).
43. Churchwell MD, Tam VH Hou JG. Colistin Clearance during Continuous Dialysis. Blood Purif 2008;26:171 (Abstract #17).
44. Peeters MJ, Churchwell MD, Mauro LS, Cappelletty DM, Stone GE. A Rasch-based Pharmacotherapeutics Textbook Selection Methodology. American Associations of Colleges of Pharmacy July 2008 Chicago, IL.
45. Salama NN, Segal J, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. Intradialytic Administration of Daptomycin in End Stage Renal Disease and Patients on Hemodialysis. J Am Soc Nephrol 2008;19:737A (Abstract #SA-PO2772).
46. Salama NN, Segal J, Churchwell MD, Patel JH, Gao L, Heung M, Mueller BA. Daptomycin Serum Concentrations are Maintained in a 2- and 3-Day Interdialytic Period. J Am Soc Nephrol 2008;19:738A (Abstract #SA-PO2773).
47. Churchwell MD. Vancomycin Clearance during Slow Low Efficiency Dialysis. Pharmacother 2009;29(10):220-221e (Abstract #135).
48. Zukkoor S, Mauro V, Churchwell M. Atorvastatin 80 mg Daily Therapy for Acute Coronary Syndrome: An Assessment of Short and Long Term Tolerability. Ohio College of Clinical Pharmacy October 2009 Cleveland, OH (Abstract #30).
49. Zukkoor S, Mauro V, Churchwell M. Atorvastatin 80 mg Daily Therapy for Acute Coronary Syndrome: An Assessment of Short and Long Term Tolerability. 44th American Society of Health-System Pharmacy 2009 Mid-Year Meeting Las Vegas, NV.
50. Murray TD, Churchwell MD, Vilay AM, Mueller BA. Anticonvulsant drug clearance by in vitro models of slow low efficiency dialysis, continuous veno-venous hemofiltration, and continuous dialysis with albumin-supplemented dialysate. 45th American Society of Health-System Pharmacy 2010 Mid-Year Meeting Anaheim, CA.
51. Churchwell MD, Jung R, Ratnam S. Early versus late conversion to sirolimus from calcineurin inhibitor based immunosuppression in adult kidney transplant recipients: a single center retrospective study. American Society of Nephrology Renal Week 2011 Philadelphia, PA.
52. Hoover MJ, Mauro VF, Gundrum TE, Churchwell MD. Evaluating the role of statins in the prevention of contrast-induced nephropathy. 46th American Society of Health-System Pharmacy 2011 Mid-Year Meeting New Orleans, LA.
53. Khan A, Churchwell M, Gundrum T, Malhotra D. Predictors of resistance to erythropoietin therapy in chronic kidney disease. 47th American Society of Health-System Pharmacy 2012 Mid-Year Meeting Las Vegas, NV.
54. Thompson, E, Churchwell M, Jung R. Bleeding Risk Associated with Antiplatelet Therapy in Chronic Kidney Disease Patients Following Acute Coronary Syndrome. 47th American Society of Health-System Pharmacy 2012 Mid-Year Meeting Las Vegas, NV.
55. Verlinden N, Thompson E, Churchwell M, Jung R. Bleeding Risk Associated with Antiplatelet Therapy in Chronic Kidney Disease Patients Following Acute Coronary Syndrome. 48th American Society of Health-System Pharmacy 2013 Mid-Year Meeting Orlando, FL.
56. Sejnowski C, Johnson K, Churchwell M, Vetteth S, Shafique I and Prashar R. Prospective Comparison of Loop diuretic and albumin infusion regimens in Patients with Acute Kidney Injury. 48th American Society of Health-System Pharmacy 2013 Mid-Year Meeting Orlando, FL.
57. Wei Y, Yang W, Boddu S.H.S, Jung R, Churchwell MD. Compatibility, stability, and efficacy of vancomycin combined with gentamicin or ethanol in sodium citrate as a catheter lock solution. Student College of Clinical Pharmacy 1st annual research symposium 2014. Toledo, OH.
58. Johnson K, Sejnowski CA, Vetteth S, Shafique I, Prashar R, Jung R, Churchwell M. Loop Diuretic Infusions With & Without Continuous Albumin Infusions in Acute Kidney Injury Patients, Society of Critical Care Medicine 2015 Phoenix, AZ.
59. Radan J, Eitniear LA; Churchwell M, Jung R, Ortiz J. The Association Between Tacrolimus Levels and Graft Loss in Renal Transplant Patients. 51st American Society of Health-System Pharmacy 2016 Mid-Year Meeting Las Vegas, NV.
60. Frank M, Boddu SH, Mauro VF, Churchwell MD. Compatibility of valproic acid injection with select cardiovascular medications. Student College of Clinical Pharmacy 4th annual research symposium 2017. Toledo, OH.